Kiadis Pharma Appoints Dr. Maarten Egeler, MD PhD as Chief Medical Officer

January 6, 2009

AMSTERDAM, January 6 /PRNewswire/ — Biopharmaceutical Company Kiadis
Pharma focused on the development of innovative cell based therapeutics in
the field of bone marrow transplantation, announces today the appointment of
Dr. Maarten Egeler as Chief Medical Officer (CMO). Dr. Egeler is a global
leading pediatric bone marrow transplantation physician and an
internationally-recognized authority in pediatric hemato-oncology. He brings
to Kiadis Pharma over more than 20 years of expertise in this field.

The appointment of Dr. Egeler is an important milestone in the
development of Kiadis Pharma’s lead product ATIR(TM) as a revolutionary
approach to provide safe and potentially life-saving mismatched bone marrow
transplantations as a treatment option for end-stage leukemia patients. Dr.
Egeler’s appointment will strongly support the upcoming multi-center pivotal
study on ATIR(TM) early 2009.

Dr. Egeler will join Kiadis Pharma part time next to his position as Head
of the Pediatric Oncology and Bone Marrow Transplantation division of the
University of Leiden. As Kiadis Pharma’s CMO, he will oversee all medical
affairs of the company and he will work closely with the company’s global
network of key opinion leaders in the transplantation community on the
development of the company’s products.

“Maarten has been acting as a medical advisor for Kiadis Pharma over the
last year and we are very pleased that he agreed to become our CMO”, says

Manja Bouman, CEO of Kiadis Pharma. “The depth of his medical expertise in
the field of bone marrow transplantations, his leadership worldwide in
haplo-identical transplantation and his network with key opinion leaders in
the field will greatly contribute to the success of our products and company”.

“I am very excited to join Kiadis Pharma in the role of CMO. I look
forward to participate in the development of its programs. I am particularly
excited to work on the ATIR(TM) product, which is aimed at preventing acute
Graft versus Host Disease and thus enables severe mismatched bone marrow
transplantation (so-called ‘haplo-identical transplantation’) and is entering
a pivotal study in early 2009″, says Maarten Egeler. “I am confident that my
background in this field within the pediatric setting will be valuable for
the company.”

    For the complete press release please go to: http://www.kiadis.com/news

    For more information please contact:
    Kiadis Pharma B.V.
    Eefje Simpelaar
    Director Communications
    Email: e.simpelaar@kiadis.com
    Tel: +31-20-3140250
    Mob: +31-6-10829344

SOURCE Kiadis Pharma

Source: newswire

comments powered by Disqus